The Medical AI Podcast Episode 60: How to make money from medical AI, with Chris Wood, CEO of RevealDX
Jul 1, 2025
Chris Wood, CEO of RevealDX and a medical physicist with a knack for commercializing imaging AI, dives deep into the financial struggles of medical AI companies. He reveals the challenging reimbursement landscape that limits profitability and discusses vital pathways like Medicare's codes. Chris shares insights on alternative funding avenues and how specific companies are finding success despite the obstacles. He also highlights RevealDX's innovative lung nodule AI product and the lessons learned from industry pioneers.
AI Snips
Chapters
Transcript
Episode notes
Career Rooted In Imaging And CAD
- Chris Wood traced his career from medical physics to founding and selling imaging companies.
- His history includes early CAD 510(k) clearance and exits that shaped his reimbursement focus.
Reimbursement Is The Industry's Financial Engine
- Reimbursement is the key scalable funding mechanism to build a sustainable medical imaging AI industry.
- Relying on efficiency gains alone won't fund the whole AI ecosystem or attract long-term investor capital.
Medicare Paths Shape Commercial Success
- Medicare payment pathways determine whether medical AI can scale commercially in the U.S.
- Temporary HOPPS codes (NTAP-like) let products gain traction before potential permanent CPT adoption.